Instil Bio subsidiary terminates license deal with ImmuneOnco for AXN-2510 and AXN-27M

Instil Bio, Inc.

Axion Bio (Instil Bio subsidiary) terminated License and Collaboration Agreement with ImmuneOnco effective Jan 5, 2026.
Agreement, dated Aug 1, 2024, granted Axion ex-China rights to AXN-2510 and AXN-27M.
No details provided on termination reason or financial impact on Instil Bio.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Instil Bio, Inc. terminated License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (effective 2026-01-05).

Action: termination
Agreement: license
Counterparty: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Effective: 2026-01-05

Exact text from the filing

Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License and Collaboration Agreement dated August 1, 2024 between ImmuneOnco and Axion

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-26-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.